Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Ligand Pharmaceuticals Incorporated is developing LGD-6972, a novel, orally-bioavailable
addition to diet and exercise to improve glycemic control in adults with type 2 diabetes
mellitus. The mechanism of action of LGD-6972 is to reduce the excess liver glucose
production characteristic of type 2 diabetes mellitus that is a major contributor to
hyperglycemia. This clinical trial will evaluate the safety and tolerability of escalating
doses LGD-6972 administered daily over 2 weeks in both healthy subjects and subjects with
type 2 diabetes mellitus.